Silexion Therapeutics (SLXN) Gets a Buy from Maxim Group
In a report released on January 27, Naz Rahman from Maxim Group reiterated a Buy rating on Silexion Therapeutics (SLXN – Research Report), with ...
Stocktwits on MSN1d
TRIB, SLXN, STSS: Why Retail Chatter On 3 Nano-Cap Healthcare Stocks Exploded Over 6000%
Three nano-cap healthcare stocks drew massive attention from retail investors on Stocktwits Tuesday, though not all for ...
Silexion Therapeutics Announces Exercise of Warrants for $3.3 Million Gross Proceeds
H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.
Yahoo Finance1d
Silexion Therapeutics Corp (SLXN)
Cayman Islands, January 29, 2025 -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion Therapeutics” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi ...
Silexion Therapeutics Reports Strong Tumor Growth Reduction from Systemic Administration of SIL-204 in Preclinical Pancreatic Cancer Models
New preclinical findings provide validation for Silexion’s new systemic administration approach for SIL-204, demonstrating ...
Silexion reports breakthrough in KRAS cancer therapy
CAYMAN ISLANDS - Silexion Therapeutics Corp. (NASDAQ: SLXN), a biotech firm focusing on RNA interference (RNAi) treatments, ...
Why Is Silexion Therapeutics Stock Soaring Over 100% On Tuesday?
Silexion Therapeutics shares preclinical data on SIL-204, highlighting tumor reduction in KRAS-driven cancers and sustained drug efficacy for 56+ days.
Silexion Therapeutics Highlights New Preclinical Data From Its Pancreatic Cancer Studies
Silexion Therapeutics' SIL-204 exhibits synergy with key pancreatic cancer drugs in preclinical studies. Phase 2/3 trials planned for 2026.
Seeking Alpha16d
SLXN Silexion Therapeutics Corp
Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages ...